Pharmafile Logo

Case study

Using qualitative conjoint to assess willingness-to-pay

Find out how Research Partnership used their proprietary ChoiceQual conjoint technique to assess and develop a market access and pricing strategy for an influenza vaccine.

Read the full case study here: https://bit.ly/2EOVl2e

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Patient Centricity: Turning Rhetoric into Reality

Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST

Making sense of Nutraceuticals in China

Published in eyeforpharma February 2017 by Marc Yates

Research Partnership has been ranked in the Pharma Times Pharma Fast 50

Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...

Women’s health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide.

PEGASUS AND UCL JOIN FORCES IN INSPIRING HEALTHY DECISIONS

Pegasus, an Ashfield company, part of UDG Healthcare plc, is proud to announce the launch of its new propriety model for planning in health – CHANGE – which was developed...

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017